Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Megestrol acetate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Megestrol acetate. Displaying page 1 of 1.
    EudraCT Number: 2016-003752-79 Sponsor Protocol Number: PIONEER Start Date*: 2017-05-24
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: Randomised Phase II clinical trial PIONEER- A Pre-operative wIndOw study of letrozole plus PR agonist (Megestrol Acetate) versus letrozole aloNE in post-menopausal patients with ER-positive breast ...
    Medical condition: ER-positive, HER2-negative, invasive primary breast cancer of at least 1 cm size
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-005148-16 Sponsor Protocol Number: BO-EPOC-01 Start Date*: 2006-07-06
    Sponsor Name:MADAUS, S.A.
    Full Title: Ensayo clínico randomizado, aleatorizado y doble ciego, para valorar el efecto del tratamiento con 320 mg al día de Acetato de Megestrol durante 8 semanas en los pacientes con Enfermedad Pulmonar O...
    Medical condition: Pacientes afectos de enfermedad pulmonar obstructiva crónica (EPOC) severa definida según consenso ATS/ERS con un FEV1 <50% del valor teórico y con bajo peso corporal o pérdida de peso de forma in...
    Disease: Version SOC Term Classification Code Term Level
    8.0 10009033 P.T.
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008857-53 Sponsor Protocol Number: DC10004 Start Date*: 2009-02-25
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Open-Label, Pilot Phase I/II Study of the Efficacy and Safety of Concomitant Megestrol + Formoterol in Patients with Cachexia and Advanced Malignancy
    Medical condition: Cancer-related cachexia, also known as Cancer Anorexia-Cachexia Syndrome (CACS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000299-15 Sponsor Protocol Number: BC1-03 Start Date*: 2004-11-03
    Sponsor Name:Algeta AS
    Full Title: A double-blind, dose-response, phase II, multicentre study of radium-223 (Alpharadin TM ) for the palliation of painful bone metastases in hormone refractory prostate cancer patients
    Medical condition: The target population is patients suffering from bone pain due to skeletal metastasis secondary to prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010613-68 Sponsor Protocol Number: X-55-58064-004 Start Date*: 2009-07-06
    Sponsor Name:Ipsen Pharma
    Full Title: A phase II international multicentre randomised open label study of oral steroid sulphatase inhibitor BN83495 versus megestrol acetate (MA) in women with advanced or recurrent endometrial cancer
    Medical condition: Advanced or recurrent endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed) FR (Completed) ES (Prematurely Ended) CZ (Completed) HU (Completed) PL (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-004545-15 Sponsor Protocol Number: MLAM 2007/01 Start Date*: 2008-06-10
    Sponsor Name:University Medical Center Utrecht
    Full Title: The Split Dose Study: Split dose Rhenium-188-HEDP regimen in hormone refractory prostate cancer patients with bone metastases; a phase I toxicity study and phase II efficacy study.
    Medical condition: Hormone refractory prostate cancer with painful bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004756-20 Sponsor Protocol Number: EFC6546 Start Date*: 2007-09-19
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastat...
    Medical condition: Patients with metastatic androgen-independent prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) SE (Completed) CZ (Completed) PT (Completed) ES (Completed) DK (Completed) HU (Completed) EE (Completed) BE (Completed) NL (Completed) IT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004647-20 Sponsor Protocol Number: COR-2017-OLE Start Date*: 2018-11-13
    Sponsor Name:Cortendo AB
    Full Title: An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome
    Medical condition: Endogenous Cushing´s syndrome (CS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) ES (Ongoing) IT (Completed) NL (Completed) GR (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001219-35 Sponsor Protocol Number: COR-2017-01 Start Date*: 2018-01-22
    Sponsor Name:Cortendo AB
    Full Title: A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenou...
    Medical condition: Endogenous Cushing´s syndrome (CS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) BG (Completed) HU (Completed) PL (Completed) NL (Completed) DK (Prematurely Ended) GR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-004564-32 Sponsor Protocol Number: NG 05 / 09 Start Date*: 2007-03-06
    Sponsor Name:University Medical center Utrecht
    Full Title: The Prostate CARE Study: Capecitabine (Xeloda®) combined with Rhenium-188-HEDP in hormone refractory prostate cancer patients with bone metastases; a Capecitabine phase I dose escalation study and...
    Medical condition: Hormone refractory prostate cancer with painful bone metastases
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000544-86 Sponsor Protocol Number: 11848 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer HealthCare AG; D-51368 Leverkusen
    Full Title: A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or me...
    Medical condition: unresectable and/or metastatic renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003847-22 Sponsor Protocol Number: ICORG11-04 Start Date*: 2012-02-02
    Sponsor Name:ICORG
    Full Title: ECOG 2809: Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
    Medical condition: Patients with Rising PSA at high risk of Prostate cancer progression
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000634-53 Sponsor Protocol Number: AP23573-07-205(8669-007) Start Date*: 2008-11-07
    Sponsor Name:Merck Sharp & Dohme Corp.,
    Full Title: A randomized phase II trial of ridaforolimus (AP23573; MK-8669) compared to progestin or chemotherapy in female adult patients with advanced endometrial carcinoma
    Medical condition: advanced endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014747 Endometrial carcinoma recurrent LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014745 Endometrial carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) CZ (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000175-43 Sponsor Protocol Number: A246 Start Date*: 2014-08-25
    Sponsor Name:AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO
    Full Title: CHemotherapy plus Enzalutamide In first line therapy for castration Resistant prOstate caNcer A multicentric Randomized phase II study. Ch.E.I.R.O.N. Trial
    Medical condition: castration Resistant prOstate caNcer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003314-97 Sponsor Protocol Number: CA184-043 Start Date*: 2009-08-05
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Do...
    Medical condition: Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) AT (Completed) NL (Completed) IT (Completed) CZ (Completed) DK (Completed) ES (Completed) IE (Completed) BE (Completed) GB (Completed) HU (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-001822-23 Sponsor Protocol Number: CEPO906A2229 Start Date*: 2006-07-29
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer
    Medical condition: Cancer of the prostate is the most commonly diagnosed neoplasm in men in the United States after skin cancer. In 2002, over 189,000 new cases were diagnosed in United States representing 30% of all...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000415-23 Sponsor Protocol Number: PM14-A-002-20 Start Date*: 2021-05-25
    Sponsor Name:Pharma Mar, S.A.
    Full Title: Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 06:59:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA